Fierce Biotech July 25, 2024
Edwards Lifesciences is dropping about $1.6 billion on a pair of acquisitions to bolster its structural heart portfolio.
They comprise JenaValve Technology, which is developing a transcatheter valve aimed at aortic regurgitation, and Endotronix, the maker of an implantable heart failure monitor.
Currently in the U.S., transcatheter aortic valve replacement systems have only been approved by the FDA for treating stenosis, where the valve narrows to the point of hampering blood flow. Edwards said that if JenaValve clears the FDA as it expects in late 2025, it may be the first minimally invasive therapy for regurgitation, where loose flaps allow blood to flow backward through the valve.
Treating aortic regurgitation has been tricky from a transcatheter approach, because the...
Today's Sponsors
Today's Sponsor